文章：

评估Delta放射组学在非小细胞肺癌患者酪氨酸激酶抑制剂治疗反应评估中的潜力

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients

原文发布日期：24 October 2023

DOI: 10.3390/cancers15215125

类型: Article

开放获取: 是

英文摘要：

Our study aimed to harness the power of CT scans, observed over time, in predicting how lung adenocarcinoma patients might respond to a treatment known as EGFR-TKI. Analyzing scans from 322 advanced stage lung cancer patients, we identified distinct image-based patterns. By integrating these patterns with comprehensive clinical information, such as gene mutations and treatment regimens, our predictive capabilities were significantly enhanced. Interestingly, the precision of these predictions, particularly related to radiomics features, diminished when data from various centers were combined, suggesting that the approach requires standardization across facilities. This novel method offers a potential pathway to anticipate disease progression in lung adenocarcinoma patients treated with EGFR-TKI, laying the groundwork for more personalized treatments. To further validate this approach, extensive studies involving a larger cohort are pivotal.

摘要翻译： 

本研究旨在利用随时间变化的CT扫描数据，预测肺腺癌患者对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的反应。通过对322例晚期肺癌患者的影像资料进行分析，我们识别出具有鉴别意义的影像组学特征模式。将这些影像特征与基因突变、治疗方案等综合临床信息相结合后，预测效能得到显著提升。值得注意的是，当整合多中心数据时，基于影像组学特征的预测精度有所下降，这表明该方法需要建立跨机构的标准化流程。这一创新方法为预测EGFR-TKI治疗的肺腺癌患者疾病进展提供了潜在途径，为推进个体化治疗奠定了基础。后续需要通过更大规模队列研究进一步验证该方法的有效性。

原文链接：

Evaluating the Potential of Delta Radiomics for Assessing Tyrosine Kinase Inhibitor Treatment Response in Non-Small Cell Lung Cancer Patients